Detalhe da pesquisa
1.
En masse organoid phenotyping informs metabolic-associated genetic susceptibility to NASH.
Cell
; 185(22): 4216-4232.e16, 2022 10 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-36240780
2.
IL-31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH.
Hepatology
; 77(1): 20-32, 2023 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35686937
3.
Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis.
Gut
; 72(3): 581-589, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36750244
4.
Acetyl-CoA carboxylase inhibitor increases LDL-apoB production rate in NASH with cirrhosis: prevention by fenofibrate.
J Lipid Res
; 64(3): 100339, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36737040
5.
Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat.
Clin Gastroenterol Hepatol
; 21(1): 143-152.e3, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34999207
6.
Safety and Sustained Efficacy of the Farnesoid X Receptor (FXR) Agonist Cilofexor Over a 96-Week Open-label Extension in Patients With PSC.
Clin Gastroenterol Hepatol
; 21(6): 1552-1560.e2, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35934287
7.
Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis.
Hepatology
; 75(5): 1235-1246, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34662449
8.
PRIMIS: design of a pivotal, randomized, phase 3 study evaluating the safety and efficacy of the nonsteroidal farnesoid X receptor agonist cilofexor in noncirrhotic patients with primary sclerosing cholangitis.
BMC Gastroenterol
; 23(1): 75, 2023 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36922785
9.
Hepatic Deletion of X-Box Binding Protein 1 in FXR Null Mice Leads to Enhanced Liver Injury.
J Lipid Res
; 63(11): 100289, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36162519
10.
Elevated de novo lipogenesis, slow liver triglyceride turnover, and clinical correlations in nonalcoholic steatohepatitis patients.
J Lipid Res
; 63(9): 100250, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35835205
11.
A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH Cirrhosis.
Hepatology
; 74(6): 3146-3160, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34333790
12.
A Fibrosis-Independent Hepatic Transcriptomic Signature Identifies Drivers of Disease Progression in Primary Sclerosing Cholangitis.
Hepatology
; 73(3): 1105-1116, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32745270
13.
A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH.
Hepatology
; 74(1): 133-147, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33570776
14.
Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH.
Hepatology
; 73(2): 625-643, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33169409
15.
Inter- and Intra-individual Variation, and Limited Prognostic Utility, of Serum Alkaline Phosphatase in a Trial of Patients With Primary Sclerosing Cholangitis.
Clin Gastroenterol Hepatol
; 19(6): 1248-1257, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32707342
16.
Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial.
Hepatology
; 72(1): 58-71, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32115759
17.
The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis.
Hepatology
; 70(3): 788-801, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30661255
18.
GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease.
Gastroenterology
; 155(5): 1463-1473.e6, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30059671
19.
Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis.
Clin Gastroenterol Hepatol
; 16(12): 1983-1991.e3, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29705265